Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | 324,218 |
| 52 Week High | $1.40 |
| 52 Week Low | $0.25 |
| Target Price | $1.26 |
| Ticker | ZYNE:UW |
| Composite Ticker | ZYNE:US |
| Security Name | Zynerba Pharmaceuticals Inc |
| Type | Ordinary Shares |
| Class | ZYNE |
| Currency | USD |
| Round Lot Size | 100 |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | Equity |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG009J96R40 |
| Composite FIGI | BBG007BBS8B7 |
| Share Class FIGI | BBG007BBS8C6 |
| FIGI Unique ID | N/A |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | N/A |
| Beta | 0.52 |
| 1-year beta | -2.3965 |
| 3-year beta | 0.52 |
| 5-year beta | 0.9909 |
| 7-year beta | 1.0225 |
| 10-year beta | 1.0445 |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
